AI Engines For more Details: Perplexity Kagi Labs You
Diuresis: Hydroflumethiazide works by increasing the excretion of water and electrolytes (sodium and chloride) in the urine, leading to a reduction in blood volume and a decrease in blood pressure. This diuretic effect helps to alleviate hypertension and reduce edema.
Lowering Blood Pressure: By reducing blood volume and decreasing peripheral vascular resistance, hydroflumethiazide helps to lower blood pressure. It is often used as a first-line treatment for hypertension, either alone or in combination with other antihypertensive medications.
Edema Reduction: Hydroflumethiazide is effective in reducing edema by promoting the elimination of excess fluid accumulated in the body tissues, particularly in conditions such as congestive heart failure and liver cirrhosis.
Electrolyte Imbalance: Thiazide diuretics like hydroflumethiazide can cause electrolyte imbalances, particularly hypokalemia (low potassium levels), hyponatremia (low sodium levels), and hypomagnesemia (low magnesium levels). Regular monitoring of electrolyte levels is important, especially in individuals at risk or those taking other medications that may affect electrolyte balance.
Dehydration: Excessive diuresis with hydroflumethiazide can lead to dehydration, especially in vulnerable populations such as the elderly or those with kidney dysfunction. Patients are advised to maintain adequate hydration and be cautious of signs and symptoms of dehydration.
Hyperuricemia: Thiazide diuretics may increase serum uric acid levels, predisposing individuals to gout or exacerbating existing gouty arthritis. Monitoring of serum uric acid levels and appropriate management strategies may be necessary in patients at risk.
Glucose Intolerance: There is evidence to suggest that thiazide diuretics like hydroflumethiazide may impair glucose tolerance and contribute to the development or worsening of diabetes mellitus. Regular monitoring of blood glucose levels is recommended, especially in patients with preexisting diabetes or those at risk for the condition.
Orthostatic Hypotension: Rapid fluid loss due to diuresis with hydroflumethiazide can lead to orthostatic hypotension, characterized by a drop in blood pressure upon standing up from a lying or sitting position. Patients should be advised to change positions slowly to minimize this risk.
Renal Function: Thiazide diuretics may affect renal function, particularly in patients with preexisting kidney disease. Close monitoring of renal function, including serum creatinine and blood urea nitrogen (BUN) levels, is recommended during therapy.
Allergic Reactions: Although rare, allergic reactions to hydroflumethiazide can occur, including skin rash, itching, and hypersensitivity reactions such as angioedema or anaphylaxis. Patients should seek medical attention if they experience any signs of an allergic reaction.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.1 | -0.1 | |
ADHD | 1 | 0 | 0 |
Age-Related Macular Degeneration and Glaucoma | 0 | 0 | |
Allergic Rhinitis (Hay Fever) | 0.2 | 0.2 | 0 |
Allergies | 0.3 | 0.7 | -1.33 |
Allergy to milk products | 0.4 | 0.1 | 3 |
Alzheimer's disease | 0.6 | 1.5 | -1.5 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.2 | 0.8 | 0.5 |
Ankylosing spondylitis | 0.3 | 0.4 | -0.33 |
Anorexia Nervosa | 0.8 | -0.8 | |
Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
Asthma | 0.1 | 0.9 | -8 |
Atherosclerosis | 0.2 | 0.4 | -1 |
Atrial fibrillation | 0.8 | 0.3 | 1.67 |
Autism | 1.4 | 2.5 | -0.79 |
Barrett esophagus cancer | 0 | 0 | |
benign prostatic hyperplasia | 0.1 | 0.1 | |
Bipolar Disorder | 0.3 | 0.2 | 0.5 |
Brain Trauma | 0.1 | 0.2 | -1 |
Carcinoma | 0.4 | 0.3 | 0.33 |
Celiac Disease | 0.3 | 0.9 | -2 |
Cerebral Palsy | 0.3 | 0.3 | 0 |
Chronic Fatigue Syndrome | 0.9 | 0.3 | 2 |
Chronic Kidney Disease | 0.2 | 0.8 | -3 |
Chronic Lyme | 0.2 | -0.2 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0 | 0.2 | 0 |
Chronic Urticaria (Hives) | 0.2 | 0.5 | -1.5 |
Coagulation / Micro clot triggering bacteria | 0.2 | 0.2 | 0 |
Colorectal Cancer | 0.6 | 0.4 | 0.5 |
Constipation | 0.4 | 0 | 0 |
Coronary artery disease | 0.4 | 0 | 0 |
COVID-19 | 1.5 | 3.3 | -1.2 |
Crohn's Disease | 0.9 | 1.7 | -0.89 |
cystic fibrosis | 0.2 | 0.2 | 0 |
deep vein thrombosis | 0.2 | 0.2 | 0 |
Depression | 1.6 | 2.3 | -0.44 |
Dermatomyositis | 0.1 | -0.1 | |
Eczema | 0.1 | 0.1 | 0 |
Endometriosis | 0.4 | 0.3 | 0.33 |
Eosinophilic Esophagitis | 0 | 0 | |
Epilepsy | 0.5 | 0.9 | -0.8 |
Fibromyalgia | 0 | 0.3 | 0 |
Functional constipation / chronic idiopathic constipation | 1.2 | 0.5 | 1.4 |
gallstone disease (gsd) | 0.2 | 0.1 | 1 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0 | 0 | |
Generalized anxiety disorder | 0.2 | 0.4 | -1 |
Gout | 0 | 0 | |
Graves' disease | 0.2 | 0 | 0 |
Halitosis | 0.1 | 0.1 | |
Hashimoto's thyroiditis | 0.5 | 0.2 | 1.5 |
Hidradenitis Suppurativa | 0 | 0 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.9 | 0.3 | 2 |
hypercholesterolemia (High Cholesterol) | 0.5 | -0.5 | |
hyperglycemia | 0.1 | 0.9 | -8 |
Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
hypertension (High Blood Pressure | 0.6 | 0.6 | 0 |
Hypothyroidism | 0.1 | -0.1 | |
Hypoxia | 0.4 | 0.4 | |
IgA nephropathy (IgAN) | 0.7 | -0.7 | |
Inflammatory Bowel Disease | 0.4 | 2.7 | -5.75 |
Insomnia | 0.1 | 0.3 | -2 |
Intelligence | 0 | 0 | |
Intracranial aneurysms | 0.3 | 0.3 | |
Irritable Bowel Syndrome | 1.3 | 1.2 | 0.08 |
Liver Cirrhosis | 0.7 | 0.7 | 0 |
Long COVID | 1.5 | 1.6 | -0.07 |
Low bone mineral density | 0.2 | -0.2 | |
Lung Cancer | 0.3 | 0.6 | -1 |
ME/CFS with IBS | 0.1 | 0.3 | -2 |
ME/CFS without IBS | 0.1 | 0.2 | -1 |
Menopause | 0.4 | 0.4 | |
Metabolic Syndrome | 1.1 | 1.3 | -0.18 |
Mood Disorders | 2.3 | 2.3 | 0 |
multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
Multiple Sclerosis | 1.1 | 1.2 | -0.09 |
Multiple system atrophy (MSA) | 0.7 | 0.2 | 2.5 |
Neuropathy (all types) | 0.2 | 0.1 | 1 |
neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.1 | 1.8 | -17 |
NonCeliac Gluten Sensitivity | 0.1 | -0.1 | |
Obesity | 1 | 1.1 | -0.1 |
obsessive-compulsive disorder | 1.1 | 1 | 0.1 |
Osteoarthritis | 0.2 | 0.1 | 1 |
Osteoporosis | 0.3 | 0.6 | -1 |
Parkinson's Disease | 1 | 0.8 | 0.25 |
Polycystic ovary syndrome | 0.3 | 0.6 | -1 |
Postural orthostatic tachycardia syndrome | 0.1 | -0.1 | |
Premenstrual dysphoric disorder | 0.1 | 0.1 | |
Psoriasis | 0.6 | 0.7 | -0.17 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.9 | 0.3 | 2 |
Rosacea | 0.2 | 0 | 0 |
Schizophrenia | 1.2 | 0.3 | 3 |
scoliosis | 0 | 0.5 | 0 |
Sjögren syndrome | 0.1 | 0.5 | -4 |
Sleep Apnea | 0.2 | 0.2 | 0 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 0.1 | 0 |
Stress / posttraumatic stress disorder | 0.6 | 0.8 | -0.33 |
Systemic Lupus Erythematosus | 0.2 | 0.4 | -1 |
Tic Disorder | 0.1 | 0.1 | 0 |
Tourette syndrome | 0.2 | 0.1 | 1 |
Type 1 Diabetes | 0.7 | 0.2 | 2.5 |
Type 2 Diabetes | 1.1 | 1.3 | -0.18 |
Ulcerative colitis | 0.4 | 1.3 | -2.25 |
Unhealthy Ageing | 0.3 | 1 | -2.33 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.